ARS-1620 is a quinazoline derivative that acts as a potent and selective covalent inhibitor of the KRAS G12C mutant protein. It is an orally bioavailable compound used in pharmaceutical research for targeting tumors harboring the KRAS G12C mutation.
Alcance del contenido: La información de esta página se refiere a la identificación química y a los contextos de suministro industrial, investigación y producción. No constituye una afirmación terapéutica, un consejo médico ni instrucciones de uso de medicamentos.
¿Adquiriendo o suministrando este compuesto?
Publique su inventario o una solicitud de compra
CAS 1698055-86-5
(S)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
covalent KRAS-G12C inhibitor
(S)-1-(4-(6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl)piperazin-1-yl)prop-2-en-1-one
covalent KRAS-G12C inhibitor
Exatecan mesilate
topoisomerase I inhibitor antineoplastic agent
Imidafenacin
active pharmaceutical ingredient
Vipivotide tetraxetan
pharmaceutical raw material
Secretin acetate
Active pharmaceutical ingredient
1-[4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl]prop-2-en-1-one
ZRPZPNYZFSJUPA-UHFFFAOYSA-N
C=CC(=O)N1CCN(CC1)C2=NC=NC3=C(C(=C(C=C32)Cl)C4=C(C=CC=C4F)O)F